Additional file 6: of The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours El AnsariRokaya CrazeMadeleine MiligyIslam Diez-RodriguezMaria NolanChristopher EllisIan RakhaEmad GreenAndrew 2018 Figure S2. SLC7A5 vs DMFS in all cases in the discovery set (A), all cases in the validation set (B), ER + low proliferation tumours in the combined discovery and validation set cases (C), ER + high proliferation tumours in the combined discovery and validation set cases (D), triple negative tumours in the combined discovery and validation set cases (E) and HER2+ tumours in the combined discovery and validation set (F). (PPTX 407 kb)